Extended indication Treatment of bipolar I disorder in adults and elderly with manic episodes with or without mixed features, monotherapy.
Therapeutic value No estimate possible yet
Registration phase No registration expected

Product

Active substance BHV-7000
Domain Neurological disorders
Reason of inclusion New medicine (specialité)
Main indication Schizophrenia, psychosis, bipolar disorder
Extended indication Treatment of bipolar I disorder in adults and elderly with manic episodes with or without mixed features, monotherapy.
Manufacturer Biohaven
Mechanism of action Receptor agonist
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks BHV-7000 is een selectieve Kv7.2/7.3-activator.

Registration

Registration route Centralised (EMA)
ATMP No
Orphan drug No
Registration phase No registration expected
Additional remarks De studie voldeed niet aan het primaire eindpunt en is uit de pijplijn van de fabrikant verwijderd.

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Duration of treatment Maximal 21 day / days
Frequency of administration 1 times a day
Dosage per administration 75 mg
References NCT06419582

Expected patient volume per year

Patient volume < 211,000

Market share is generally not included unless otherwise stated.

References 1: Multidisciplinaire richtlijn bipolaire stoornissen. Trimbos-instituut. 2015. 2:
Additional remarks Naar schatting heeft 1,3% van de Nederlanders een bipolaire stoornis. Dat zijn ongeveer 211.000 personen, waaronder vrijwel evenveel mannen en vrouwen (1).

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information